NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas - sprookjes - yvandenbroek - TriplyDB

NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas

NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas

http://www.wikidata.org/entity/Q35001777

about

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas Pancreatic insulinomas: Laparoscopic management Management of gastric polyps: an endoscopy-based approach Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.Well-differentiated neuroendocrine tumor of the stomach: A rare case at an uncommon site.Non-functioning pancreatic neuroendocrine tumors: Surgery or observation?Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms): Report of 5 cases and review of the literature.Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.Minimally invasive distal pancreatectomy for PNETs: laparoscopic or robotic approach?Pancreatic neuroendocrine tumor Grade 1 patients followed up without surgery: Case series Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.Gastric neuroendocrine tumours.Therapy for metastatic pancreatic neuroendocrine tumors.Update on pancreatic neuroendocrine tumors.PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma.RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner Important of case-reports/series, in rare diseases: Using neuroendocrine tumors as an example.Practical management and treatment of pancreatic neuroendocrine tumors.Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies.Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinica Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors A multimodal approach to the management of neuroendocrine tumour liver metastases Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.Behavior of Small, Asymptomatic, Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PNETs).Antitumor effects of somatostatin analogs in neuroendocrine tumors.Multiple Endocrine Neoplasia: Genetics and Clinical Management.Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET)Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice.Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors The expanding role of somatostatin analogs in the management of neuroendocrine tumors.Diagnosis of Zollinger-Ellison syndrome: increasingly difficult.Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors.Pancreatic Neuroendocrine Tumors: an Update.

P2860

Q24603675-E324CEBB-6A91-4DA1-92CA-26E97281FEE5 Q26752757-05009CB4-CE7D-424E-8B9E-1C8A171D97AE Q26777226-D4CAFEA4-AB1D-43D5-8F00-7FA3DC705E5B Q26864650-292B4300-2F71-4C2A-9A2F-3FC5B2A6D2B6 Q30249051-C09D725E-DC3E-4BCB-A5DE-0CDE6D0472E2 Q30276310-9DA558B3-5B53-435E-AD92-237679B4ACC4 Q33573118-C7C93469-18E7-4972-B61D-1163C9715808 Q33606047-FB8A6512-FE95-47FC-82F2-72A3FABA4509 Q33737587-D1B7D4AE-3A63-4200-8555-01C3385FE966 Q33779718-1A70A0C1-9122-49E9-A0A2-7C155771FAFF Q33779897-7B31D1C4-22D5-449D-9FED-1B81D2F63FAD Q34157385-B8303676-00D3-4A2F-BDB9-0A7E9394DAC9 Q34306680-D40EC70C-C3DF-488A-AE86-42292B0797AE Q34357869-200A6114-AE7C-4F5F-B981-B9CF0EFDE639 Q34453043-C0191588-7A00-4DDB-81A5-8883D236B67C Q34484195-C021FCF5-0AEB-4CD7-8AD4-9CCA326CB9F7 Q34518263-C2141319-B875-41FA-A609-C0644E4F3D19 Q34520056-F909CDD9-4509-4DFE-B512-0C3714E50A22 Q34573600-20E96C8C-D364-4CAA-B768-83A4DDD53D43 Q34650411-7B74A248-A32B-41C6-A59B-30D192AB539F Q35009459-6B5E15D0-3E13-4C53-B36E-77D0AB827CAC Q35034000-61AABC0B-BB07-4CB7-A688-AF4FE7EEB054 Q35128224-2218816B-7BA6-4813-AD17-DA42768DD56C Q35440550-BC26738A-4160-4941-8E5A-21953D7B447A Q35640506-BCD01278-684F-4BE5-B9D8-56CF0E18CD51 Q35675435-FDDD13BB-5CE7-41C4-8476-070C872108A4 Q35677887-886E73E5-507E-4C6B-81A1-121F5AB30336 Q35747137-00AC8327-166F-4BFC-AC46-B00CA5A10D2C Q35810562-F1AE658A-0395-4351-8B07-6304E7C5FB94 Q35843079-7EB71513-AC62-4F03-9AE7-29B43E695356 Q35857794-634AE3B5-0F4A-4EFB-9491-5DD33996DEDF Q36051476-854CE499-4131-4AD7-8DDC-568A08AE9619 Q36063577-1446CEF1-CC6D-4CCF-8ACD-1C698679209C Q36065003-092F7A78-5456-4953-8A99-29890142FA3A Q36084862-79D126A0-434E-4E2F-841C-273E358D7CA4 Q36330126-762830A1-265C-45A4-B7D7-8AE7A0078BD1 Q36347272-1CCB84B4-3EBE-471B-87C6-4308C701B0C4 Q36351873-490E1104-AF21-4482-AB10-8D1FC2A5AFFF Q36395571-6E9BFD09-B2D3-4C99-BBAC-7FFF6051F4AF Q36400062-057980C8-D77D-41F4-A2C1-B95B75D13777

P2860

NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas

http://www.wikidata.org/entity/Q35001777

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

NANETS treatment guidelines: w ...... rs of the stomach and pancreas

@ast

NANETS treatment guidelines: w ...... rs of the stomach and pancreas

@en

type

label

NANETS treatment guidelines: w ...... rs of the stomach and pancreas

@ast

NANETS treatment guidelines: w ...... rs of the stomach and pancreas

@en

prefLabel

NANETS treatment guidelines: w ...... rs of the stomach and pancreas

@ast

NANETS treatment guidelines: w ...... rs of the stomach and pancreas

@en

P1433

Q35001777-FC5673D7-2DF3-4FB7-90CB-F5832806215D

P1476

Q35001777-4FCA0EEB-ED6F-4639-8C23-7D9BBA95D93A

P2093

Q35001777-0E8E81A9-AF25-4AA3-AB0A-707C351E41D9

Q35001777-143BBC43-E839-4A0B-8E30-BE2F279A0FDE

Q35001777-2DFE2CCC-6EDC-42A6-A965-E4A0BE3FE4F9

Q35001777-3281A217-4F96-40F7-A648-553902F37B83

Q35001777-65D7ED05-3552-4579-901A-E7497346F6D4

Q35001777-6C313835-1A2E-408A-AB9F-41B6D292B822

Q35001777-9842E0FB-24A0-4CCD-B798-D24C64581C69

Q35001777-98D52F71-035D-4502-B046-A45203720A3D

Q35001777-A82BC4BE-D22B-4ACC-9ED0-A63CBDCDBCB8

Q35001777-C436E4A5-F9F6-46D4-88F0-99A4C83506DA

P2860

Q35001777-00102AF8-AC59-46AE-89C5-FE80C0F7012B

Q35001777-0122D7F2-1230-454F-9D80-3EE53E89593F

Q35001777-0810479D-462B-4F6B-AE40-61BEBD6C725C

Q35001777-081F1F8F-A304-4703-BF35-F499FC6C617A

Q35001777-093BF118-F317-4755-81D7-A24EBA2CA4EC

Q35001777-0A4CC634-6765-4CE7-9277-EEEC7105918D

Q35001777-0A757F31-9190-4A39-9F8D-16E72B2A3D6C

Q35001777-0B913009-B7FE-48B3-A801-4510B95262E1

Q35001777-1039F19C-EC3C-4D1E-A1EB-ED6A37639EE5

Q35001777-104E3B4C-45BF-4B55-8AFF-71297EEAF9F5

P304

Q35001777-E778C8A8-7721-419A-B427-1389EEE070C0

P31

Q35001777-54F3FBB0-427B-41EC-919E-0DAE281F84C3

P356

Q35001777-984CEB37-E3D7-47E3-8526-7A881406A37E

P433

Q35001777-6B51F934-52C0-42A4-BEBF-0FCCBD8BF21A

P478

Q35001777-FC1095CE-6697-42F8-82EF-3B767CA045CB

P50

Q35001777-C09B3F43-BF4F-4272-8596-B9F7A10CD2CE

Q35001777-CF539878-E5E9-4EA3-9A24-DA652EBF5ABE

Q35001777-D95C247D-B4BD-427C-A5F8-E20C5C85FC21

P577

Q35001777-61DB2454-8075-431D-8AC7-97BDD4768A2B

P5875

Q35001777-2656022A-8573-480A-8C0E-F2CE714372D6

P698

Q35001777-4450C31E-9ECC-4D7B-AE6E-C8EA3ABDF404

P921

Q35001777-B8D26AB7-9346-441E-AFF1-1226D769ABF5

P932

Q35001777-116B2CD4-BC3D-4D57-B2E0-F0B1734DA3A9

P356

MPA.0B013E3181EBB168

P1433

P1476

NANETS treatment guidelines: w ...... rs of the stomach and pancreas

@en

P2093

David S Klimstra

http://www.w3.org/2001/XMLSchema#string

James C Yao

http://www.w3.org/2001/XMLSchema#string

Janice L Pasieka

http://www.w3.org/2001/XMLSchema#string

Lowell B Anthony

http://www.w3.org/2001/XMLSchema#string

Matthew H Kulke

http://www.w3.org/2001/XMLSchema#string

North American Neuroendocrine Tumor Society (NANETS)

http://www.w3.org/2001/XMLSchema#string

Robert T Jensen

http://www.w3.org/2001/XMLSchema#string

Rodney F Pommier

http://www.w3.org/2001/XMLSchema#string

Stanley J Goldsmith

http://www.w3.org/2001/XMLSchema#string

Stephen J Marx

http://www.w3.org/2001/XMLSchema#string

P2860

Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies

Multiple endocrine neoplasia

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

Pancreatic endocrine tumors

Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors

The glucagonoma syndrome and necrolytic migratory erythema: a clinical review

Spectrum of malignant somatostatin-producing neuroendocrine tumors.

Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years.

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.

Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.

P304

735-752

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MPA.0B013E3181EBB168

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

North American Neuroendocrine Tumor Society

Wouter W de Herder

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45389426

http://www.w3.org/2001/XMLSchema#string

P698

20664472

http://www.w3.org/2001/XMLSchema#string

P921

Aizkuņģa dziedzeris

P932

3100728

http://www.w3.org/2001/XMLSchema#string